Adherence to Oral Treatments for MS is Poor

Key clinical point: Adherence to current oral therapies for multiple sclerosis (MS) is poor.

Major finding: Almost half of patients with MS discontinue their initial oral therapy.

Study details: A retrospective administrative claims study of 8,251 patients with MS.

Disclosures: The authors received no financial support for this study. Dr. Nicholas reported receiving grant support from EMD Serono.

Citation: Nicholas J et al. CMSC 2019. Abstract DXT34.

Key clinical point: Adherence to current oral therapies for multiple sclerosis (MS) is poor.

Major finding: Almost half of patients with MS discontinue their initial oral therapy.

Study details: A retrospective administrative claims study of 8,251 patients with MS.

Disclosures: The authors received no financial support for this study. Dr. Nicholas reported receiving grant support from EMD Serono.

Citation: Nicholas J et al. CMSC 2019. Abstract DXT34.

Key clinical point: Adherence to current oral therapies for multiple sclerosis (MS) is poor.

Major finding: Almost half of patients with MS discontinue their initial oral therapy.

Study details: A retrospective administrative claims study of 8,251 patients with MS.

Disclosures: The authors received no financial support for this study. Dr. Nicholas reported receiving grant support from EMD Serono.

Citation: Nicholas J et al. CMSC 2019. Abstract DXT34.